Advertisement

Beyond Cervical Cancer: Burden of Other HPV-Related Cancers Among Men and Women

  • Anil K. Chaturvedi
    Correspondence
    Address correspondence to: Anil K. Chaturvedi, Ph.D., Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, EPS 7072, Rockville, MD 20852.
    Affiliations
    Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, Rockville, Maryland
    Search for articles by this author

      Abstract

      Human papillomavirus (HPV) infection is a necessary cause of cervical cancer, and is etiologically associated with a subset of cancers of the anus, oropharynx, penis, vagina, and vulva. Current data indicate that HPV infection is potentially associated with 90%–93% of anal cancers, 12%–63% of oropharyngeal cancers, 36%–40% of penile cancers, 40%–64% of vaginal cancers, and 40%–51% of vulvar cancers. HPV infection accounts for up to 492,800 cervical cancers and 97,215 cases of noncervical HPV-related cancers worldwide during 2002, including up to 50,780 cancers among men (13,485 anal cancers, 26,775 oropharyngeal cancers, and 10,520 penile cancers) and up to 46,435 cancers among women (14,787 anal cancers, 6,048 oropharyngeal cancers, and 25,600 vaginal/vulvar cancers). In the United States annually (1998–2003), up to 10,846 cervical cancers, 4,753 noncervical cancers among men, and 4,128 noncervical cancers among women are potentially attributable to HPV infection. Incidence rates for cervical cancer have declined significantly during the past 30 years in the United States, consistent with the success of Pap smear screening. However, incidence rates for anal, oropharyngeal, and vulvar cancers have increased substantially in recent years. The high proportion of cervical and noncervical cancers caused by HPV types 16 and 18, that is, 70%–76% for cervical cancers and 63%–95% for noncervical cancers, underscores the potential for prevention of a majority of cervical as well as noncervical HPV-related cancers through prophylactic HPV vaccination.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Adolescent Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • de Villiers E.M.
        • Fauquet C.
        • Broker T.R.
        • Bernard H.U.
        • zur H.H.
        Classification of papillomaviruses.
        Virology. 2004; 324: 17-27
        • Munger K.
        • Howley P.M.
        Human papillomavirus immortalization and transformation functions.
        Virus Res. 2002; 89: 213-228
        • Walboomers J.M.
        • Jacobs M.V.
        • Manos M.M.
        • et al.
        Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
        J Pathol. 1999; 189: 12-19
        • IARC
        IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. Vol 90. IARC Press, Lyon, France2007
        • Gillison M.L.
        • Shah K.V.
        Chapter 9: Role of mucosal human papillomavirus in nongenital cancers.
        J Natl Cancer Inst Monogr. 2003; : 57-65
        • Gillison M.L.
        • Chaturvedi A.K.
        • Lowy D.R.
        HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.
        Cancer. 2008; 113: 3036-3046
        • Parkin D.M.
        • Bray F.
        Chapter 2: The burden of HPV-related cancers.
        Vaccine. 2006; 24: S11-S25
        • Parkin D.M.
        The global health burden of infection-associated cancers in the year 2002.
        Int J Cancer. 2006; 118: 3030-3044
        • Hill A.B.
        The environment and disease: Association or causation?.
        Proc R Soc Med. 1965; 58: 295-300
      1. Adelstein DJ, Ridge JA, Gillison ML, et al. Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. 2009 September 29;31(11):1393–422.

        • Paavonen J.
        • Jenkins D.
        • Bosch F.X.
        • et al.
        Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomized controlled trial.
        Lancet. 2007; 369: 2161-2170
        • Garland S.M.
        • Hernandez-Avila M.
        • Wheeler C.M.
        • et al.
        Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
        N Engl J Med. 2007; 356: 1928-1943
      2. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
        N Engl J Med. 2007; 356: 1915-1927
      3. Giuliano AR, Palefsky J. Quadrivalent HPV vaccine efficacy against male genital disease and infection. In: Proceedings of the 25th International Papillomavirus Conference, May 8–14, 2009, Malmo, Sweden.

        • Fleurence R.L.
        • Dixon J.M.
        • Milanova T.F.
        • Beusterien K.M.
        Review of the economic and quality-of-life burden of cervical human papillomavirus disease.
        Am J Obstet Gynecol. 2007; 196: 206-212
        • Hu D.
        • Goldie S.
        The economic burden of noncervical human papillomavirus disease in the United States.
        Am J Obstet Gynecol. 2008; 198: 500-507
        • Chaturvedi A.K.
        • Madeleine M.M.
        • Biggar R.J.
        • Engels E.A.
        Risk of human papillomavirus-associated cancers among persons with AIDS.
        J Natl Cancer Inst. 2009; 101: 1120-1130
        • Chaturvedi A.K.
        • Engels E.A.
        • Gilbert E.S.
        • et al.
        Second cancers among 104,760 survivors of cervical cancer: Evaluation of long-term risk.
        J Natl Cancer Inst. 2007; 99: 1634-1643
        • Chaturvedi A.K.
        • Engels E.A.
        • Anderson W.F.
        • Gillison M.L.
        Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States.
        J Clin Oncol. 2008; 26: 612-619
        • Gillison M.L.
        • Koch W.M.
        • Capone R.B.
        • et al.
        Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.
        J Natl Cancer Inst. 2000; 92: 709-720
        • Dai M.
        • Clifford G.M.
        • le Calvez F.
        • et al.
        Human papillomavirus type 16 and TP53 mutation in oral cancer: Matched analysis of the IARC multicenter study.
        Cancer Res. 2004; 64: 468-471
        • Braakhuis B.J.
        • Snijders P.J.
        • Keune W.J.
        • et al.
        Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus.
        J Natl Cancer Inst. 2004; 96: 998-1006
        • Licitra L.
        • Perrone F.
        • Bossi P.
        • et al.
        High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma.
        J Clin Oncol. 2006; 24: 5630-5636
        • Gillison M.L.
        Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity.
        Semin Oncol. 2004; 31: 744-754
        • Fakhry C.
        • Gillison M.L.
        Clinical implications of human papillomavirus in head and neck cancers.
        J Clin Oncol. 2006; 24: 2606-2611
        • Kumar B.
        • Cordell K.G.
        • Lee J.S.
        • et al.
        EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.
        J Clin Oncol. 2008; 26: 3128-3137
        • Weinberger P.M.
        • Yu Z.
        • Haffty B.G.
        • et al.
        Molecular classification identifies a subset of human papillomavirus—associated oropharyngeal cancers with favorable prognosis.
        J Clin Oncol. 2006; 24: 736-747
        • Schlecht N.F.
        Prognostic value of human papillomavirus in the survival of head and neck cancer patients: An overview of the evidence.
        Oncol Rep. 2005; 14: 1239-1247
        • Fakhry C.
        • Westra W.H.
        • Li S.
        • et al.
        Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
        J Natl Cancer Inst. 2008; 100: 261-269
        • Ragin C.C.
        • Taioli E.
        Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta-analysis.
        Int J Cancer. 2007; 121: 1813-1820
        • Schiffman M.
        • Castle P.E.
        • Jeronimo J.
        • Rodriguez A.C.
        • Wacholder S.
        Human papillomavirus and cervical cancer.
        Lancet. 2007; 370: 890-907
        • Castle P.E.
        • Rodriguez A.C.
        • Porras C.
        • et al.
        A comparison of cervical and vaginal human papillomavirus.
        Sex Transm Dis. 2007; 34: 849-855
        • Giuliano A.R.
        • Lu B.
        • Nielson C.M.
        • et al.
        Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men.
        J Infect Dis. 2008; 198: 827-835
        • Palefsky J.M.
        • Rubin M.
        The epidemiology of anal human papillomavirus and related neoplasia.
        Obstet Gynecol Clin North Am. 2009; 36: 187-200
      4. Gardasil.
        ([package insert]) Merck & Co., Inc., Whitehouse Station, NJ2009
      5. Cervarix.
        ([package insert]) GlaxoSmithKline, Research Triangle Park, NC2009
        • Petaja T.
        • Keranen H.
        • Karppa T.
        • et al.
        Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years.
        J Adolesc Health. 2009; 44: 33-40
        • Reisinger K.S.
        • Block S.L.
        • Lazcano-Ponce E.
        • et al.
        Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: A randomized controlled trial.
        Pediatr Infect Dis J. 2007; 26: 201-209
        • Schiller J.T.
        • Lowy D.R.
        Prospects for cervical cancer prevention by human papillomavirus vaccination.
        Cancer Res. 2006; 66: 10229-10232
        • Hildesheim A.
        • Herrero R.
        • Wacholder S.
        • et al.
        Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial.
        JAMA. 2007; 298: 743-753
        • Paavonen J.
        • Naud P.
        • Salmeron J.
        • et al.
        Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomized study in young women.
        Lancet. 2009; 374: 301-314
      6. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER∗Stat Database: Incidence-SEER 9 Regs Public-Use, November 2008 Submission (1973-2006)—Linked to County Attributes—Total U.S., 1969-2003 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission, 2009.

        • Wang S.S.
        • Sherman M.E.
        • Hildesheim A.
        • Lacey Jr., J.V.
        • Devesa S.
        Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000.
        Cancer. 2004; 100: 1035-1044
        • Johnson L.G.
        • Madeleine M.M.
        • Newcomer L.M.
        • Schwartz S.M.
        • Daling J.R.
        Anal cancer incidence and survival: The surveillance, epidemiology, and end results experience, 1973-2000.
        Cancer. 2004; 101: 281-288
        • Joseph D.A.
        • Miller J.W.
        • Wu X.
        • et al.
        Understanding the burden of human papillomavirus-associated anal cancers in the US.
        Cancer. 2008; 113: 2892-2900
        • Ryerson A.B.
        • Peters E.S.
        • Coughlin S.S.
        • et al.
        Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003.
        Cancer. 2008; 113: 2901-2909
        • Judson P.L.
        • Habermann E.B.
        • Baxter N.N.
        • Durham S.B.
        • Virnig B.A.
        Trends in the incidence of invasive and in situ vulvar carcinoma.
        Obstet Gynecol. 2006; 107: 1018-1022
        • Saraiya M.
        • Watson M.
        • Wu X.C.
        • et al.
        Incidence of in situ and invasive vulvar cancer in the United States, 1998-2003.
        Cancer. 2008; 113: 2865-2872
        • Barnholtz-Sloan J.S.
        • Maldonado J.L.
        • Pow-sang J.
        • Giuliano A.R.
        Incidence trends in primary malignant penile cancer.
        Urol Oncol. 2007; 25: 361-367
        • Hernandez B.Y.
        • Barnholtz-Sloan J.
        • German R.R.
        • et al.
        Burden of penile cancer in the United States.
        Cancer. 2008; 113: 2883-2891
      7. Current trends premarital sexual experience among adolescent women—United States, 1970-1988.
        MMWR Morb Mortal Wkly Rep. 1991; 39: 929-932
        • Gillison M.L.
        Current topics in the epidemiology of oral cavity and oropharyngeal cancers.
        Head Neck. 2007; 29: 779-792
      8. Condyloma acuminatum—United States, 1966-1981.
        MMWR Morb Mortal Wkly Rep. 1983; 32: 306-308
        • Bodelon C.
        • Madeleine M.M.
        • Voigt L.F.
        • Weiss N.S.
        Is the incidence of invasive vulvar cancer increasing in the United States?.
        Cancer Causes Control. 2009; 20: 1779-1782
        • Frisch M.
        • Biggar R.J.
        • Goedert J.J.
        Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome.
        J Natl Cancer Inst. 2000; 92: 1500-1510
        • Grulich A.E.
        • van Leeuwen M.T.
        • Falster M.O.
        • Vajdic C.M.
        Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis.
        Lancet. 2007; 370: 59-67
        • Mocroft A.
        • Ledergerber B.
        • Katlama C.
        • et al.
        Decline in the AIDS and death rates in the EuroSIDA study: An observational study.
        Lancet. 2003; 362: 22-29
      9. Chaturvedi AK, Mbulaiteye SM, Engels EA. Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers. Ann Epidemiol, in press.

        • Centers for Disease Control and Prevention
        HIV/AIDS Surveillance Report, 2002.
        U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA2003 (Report No 14)